DekaBank Deutsche Girozentrale increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 3.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 188,912 shares of the medical research company’s stock after buying an additional 5,437 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Edwards Lifesciences Corporation were worth $22,251,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. South Texas Money Management Ltd. raised its position in Edwards Lifesciences Corporation by 157.9% in the first quarter. South Texas Money Management Ltd. now owns 344,816 shares of the medical research company’s stock valued at $32,437,000 after buying an additional 211,119 shares during the period. Financial Counselors Inc. raised its position in Edwards Lifesciences Corporation by 2.1% in the first quarter. Financial Counselors Inc. now owns 13,637 shares of the medical research company’s stock valued at $1,283,000 after buying an additional 282 shares during the period. American Century Companies Inc. raised its position in Edwards Lifesciences Corporation by 7.2% in the first quarter. American Century Companies Inc. now owns 2,046,875 shares of the medical research company’s stock valued at $192,550,000 after buying an additional 137,934 shares during the period. Advisor Partners LLC raised its position in Edwards Lifesciences Corporation by 7.5% in the first quarter. Advisor Partners LLC now owns 4,895 shares of the medical research company’s stock valued at $460,000 after buying an additional 341 shares during the period. Finally, Torch Wealth Management LLC acquired a new position in Edwards Lifesciences Corporation during the first quarter valued at $1,635,000. 84.15% of the stock is owned by institutional investors and hedge funds.

Shares of Edwards Lifesciences Corporation (EW) opened at 114.50 on Friday. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75. The company has a market cap of $24.18 billion, a PE ratio of 34.73 and a beta of 0.63. The company has a 50 day moving average of $116.95 and a 200-day moving average of $105.35.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.88 by $0.20. The business had revenue of $842 million for the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.76 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

WARNING: This story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/12/dekabank-deutsche-girozentrale-has-22-25-million-stake-in-edwards-lifesciences-corporation-nyseew.html.

Several research analysts have recently weighed in on EW shares. Vetr raised Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $116.04 price objective for the company in a research report on Thursday, May 4th. BidaskClub raised Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 22nd. Jefferies Group LLC reissued a “buy” rating on shares of Edwards Lifesciences Corporation in a research report on Wednesday, April 26th. Zacks Investment Research raised Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price objective for the company in a research report on Tuesday, July 18th. Finally, Cowen and Company reissued an “outperform” rating and issued a $135.00 price objective (up from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Edwards Lifesciences Corporation has a consensus rating of “Buy” and a consensus target price of $121.13.

In other news, VP Catherine M. Szyman sold 4,681 shares of Edwards Lifesciences Corporation stock in a transaction on Monday, July 31st. The shares were sold at an average price of $115.78, for a total transaction of $541,966.18. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Patrick B. Verguet sold 11,500 shares of Edwards Lifesciences Corporation stock in a transaction on Monday, May 15th. The stock was sold at an average price of $111.64, for a total transaction of $1,283,860.00. The disclosure for this sale can be found here. Insiders have sold a total of 183,412 shares of company stock worth $21,176,230 in the last quarter. Corporate insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.